JP2011505833A5 - - Google Patents

Info

Publication number

JP2011505833A5

JP2011505833A5 JP2010538109A JP2010538109A JP2011505833A5 JP 2011505833 A5 JP2011505833 A5 JP 2011505833A5 JP 2010538109 A JP2010538109 A JP 2010538109A JP 2010538109 A JP2010538109 A JP 2010538109A JP 2011505833 A5 JP2011505833 A5 JP 2011505833A5

Authority

JP

Japan

Prior art keywords

dsrna

nucleotide

sequence

seq

factor vii

Prior art date

2008-12-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003729 nucleotide group Chemical group 0.000 claims description 39
• 239000002773 nucleotide Substances 0.000 claims description 28
• 108010023321 Factor VII Proteins 0.000 claims description 14
• 102100023804 Coagulation factor VII Human genes 0.000 claims description 9
• 230000000295 complement effect Effects 0.000 claims description 9
• 229940012413 factor vii Drugs 0.000 claims description 9
• 230000014509 gene expression Effects 0.000 claims description 7
• 108020004999 messenger RNA Proteins 0.000 claims description 7
• 108091081021 Sense strand Proteins 0.000 claims description 5
• 230000000692 anti-sense effect Effects 0.000 claims description 5
• 238000000034 method Methods 0.000 claims description 5
• 208000028227 Viral hemorrhagic fever Diseases 0.000 claims description 3
• 230000002401 inhibitory effect Effects 0.000 claims description 3
• 230000003834 intracellular effect Effects 0.000 claims description 3
• 229920002477 rna polymer Polymers 0.000 claims description 3
• 208000035657 Abasia Diseases 0.000 claims description 2
• 108020004459 Small interfering RNA Proteins 0.000 claims description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 210000004185 liver Anatomy 0.000 claims description 2
• 125000001921 locked nucleotide group Chemical group 0.000 claims description 2
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
• ONKSSDKXDIVIHK-UHFFFAOYSA-N n,n-didecyldodecanamide Chemical group CCCCCCCCCCCC(=O)N(CCCCCCCCCC)CCCCCCCCCC ONKSSDKXDIVIHK-UHFFFAOYSA-N 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims description 2
• 150000008298 phosphoramidates Chemical class 0.000 claims description 2
• 230000001105 regulatory effect Effects 0.000 claims description 2
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
• 239000000203 mixture Substances 0.000 claims 3
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
• 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
• 230000005764 inhibitory process Effects 0.000 claims 2
• 238000000338 in vitro Methods 0.000 claims 1
• 230000002265 prevention Effects 0.000 description 1